Last reviewed · How we verify
Bicarbonate Hydration
Bicarbonate Hydration, marketed by Memorial University of Newfoundland, is a therapeutic solution currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity and potential revenue protection. The primary risk lies in the lack of clear competitive differentiation and the absence of significant trial results to support its efficacy and safety profile.
At a glance
| Generic name | Bicarbonate Hydration |
|---|---|
| Also known as | Sodium Bicarbonate(130 mEq/L) in 4.35% dextrose |
| Sponsor | Memorial University of Newfoundland |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction. (PHASE4)
- The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide Poisoning (NA)
- Study Evaluating Patients With Cystinuria (PHASE2, PHASE3)
- The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress (NA)
- PrevenTion of Contrast-inducEd nephroAThy With urinE Alkalinization (PHASE3)
- RenalGuard System and Contrast Media (PHASE3)
- The Effect of AMP Human Sodium Bicarbonate Lotion on Hydration (NA)
- Impact of Nuun Instant on Hydration Status in Active Men and Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bicarbonate Hydration CI brief — competitive landscape report
- Bicarbonate Hydration updates RSS · CI watch RSS
- Memorial University of Newfoundland portfolio CI